RxDoctor Payments Data

Katie Warren, DO

Neurology · Meadville, PANPI 1477879856

Payments from drug & device makers

$18,939in general payments, 2019–2025

Across 545 payments — averaging $34.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$10K
  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$644
  • Biogen$535
  • Jazz Pharmaceuticals Inc.$468
  • Pfizer$321
  • plus $5K from 53 others

What the payments were for

  • Consulting fees$8,17043%
  • Travel & lodging$1,0686%
  • Food & beverage$9,31749%
  • Education$3852%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.35$9,718
AbbVie(2 entities)197$2,584
Teva Pharmaceuticals USA, Inc.22$644
Biogen22$535
Jazz Pharmaceuticals Inc.10$468
Pfizer37$321
EMD Serono, Inc.9$295
Biohaven Pharmaceuticals, Inc.14$279
AstraZeneca7$253
Novartis25$240
Eisai Inc.13$228
Amgen12$219
Boston Scientific5$206
Lilly USA, LLC11$204
Johnson & Johnson3$174
Sanofi7$165
TG Therapeutics, Inc.3$164
Biohaven Pharmaceutical Holding Company Ltd.19$159
Lundbeck LLC8$150
Livanova USA, Inc.7$146
MDD US Operations, LLC2$124
Genentech USA, Inc.5$124
SK Life Science, Inc.4$98
E.r. Squibb & Sons, L.L.C.2$89
Neurelis, Inc.3$83
Argenx US, Inc.4$77
Kyowa Kirin, Inc.4$71
Sunovion Pharmaceuticals Inc.5$71
Harmony Biosciences LLC2$63
Amneal Pharmaceuticals LLC3$60
Neurocrine Biosciences, Inc.2$60
Ipsen Biopharmaceuticals, Inc3$58
Nevro Corp.1$55
Acadia Pharmaceuticals Inc3$55
Bristol Myers Squibb3$53
Xeris Pharmaceuticals, Inc.3$46
Medtronic2$46
Adamas Pharmaceuticals, Inc.3$45
Inspire Medical Systems, Inc.1$43
Tanabe Pharma America, Inc.2$38
Vanda Pharmaceuticals Inc.1$36
Abbott2$35
Upsher-smith Laboratories LLC1$31
Amylyx Pharmaceuticals, Inc.1$29
CSL Behring2$28
Catalyst Pharmaceuticals, Inc.1$27
Takeda Pharmaceuticals U.S.A., Inc.1$27
Strongbridge US Inc.1$23
Nobelpharma America, LLC1$22
Banner Life Sciences, LLC1$21
GE HealthCare2$20
Axsome Therapeutics, Inc.1$19
Merck1$19
Akcea Therapeutics, Inc.1$18
Avion Pharmaceuticals1$17
Currax Pharmaceuticals LLC1$17
Monteris Medical Corporation1$15
Otsuka America Pharmaceutical, Inc.1$13
Mallinckrodt Enterprises LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,939 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$35,882
Medicare patients
234
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZeposiaOzanimod Hydrochloride16$198,378
Kesimpta PenOfatumumab18$193,543
Avonex Pen (4 Pack)Interferon Beta-1a14$118,057
FingolimodFingolimod Hcl18$80,890
Nurtec OdtRimegepant Sulfate53$72,407
AmpyraDalfampridine13$57,607
Aimovig AutoinjectorErenumab-Aooe53$46,663
NuedextaDextromethorphan Hbr/Quinidine26$40,374
Emgality PenGalcanezumab-Gnlm52$36,476
MyrbetriqMirabegron13$13,677
Ajovy AutoinjectorFremanezumab-Vfrm11$13,433
SunosiSolriamfetol Hcl12$9,540
LyricaPregabalin14$9,343
ImitrexSumatriptan Succinate14$9,060
Entacapone15$5,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Zeposia$89$198,37816 claims
PfizerNurtec Odt, Lyrica$321$81,75067 claims
Axsome Therapeutics, Inc.Sunosi$19$9,54012 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$60$2,48018 claims
Upsher-smith Laboratories LLCTopiramate$31$2,329101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Meadville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →